Figure S3 from Treatment of prostate cancer with CD46 targeted ²²⁵Ac alpha particle radioimmunotherapy

Anil P. Bidkar; Sinan Wang; Kondapa Naidu Bobba; Emily Chan; Scott Bidlingmaier; Emily A. Egusa; Robin Peter; Umama Ali; Niranjan Meher; Anju Wadhwa; Suchi Dhrona; Chandrashekhar Dasari; Denis Beckford-Vera; Yang Su; Ryan Tang; Li Zhang; Jiang He; David M. Wilson; Rahul Aggarwal; Henry F. VanBrocklin; Youngho Seo; Jonathan Chou; Bin Liu; Robert R. Flavell

doi:10.1158/1078-0432.27030400.v1

Abstract

Figure S3: Binding of [225Ac]DOTA-YS5 to 22Rv1 with or without cold antibody blocking. Blocking with cold YS5 results in a reduction of binding from 19.25±0.70% to 4.46±0.17% (n=3).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bidkar et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875239ee https://doi.org/10.1158/1078-0432.27030400.v1

View at Publisher

Ask AI

Bookmark

Share

Figure S3 from Treatment of prostate cancer with CD46 targeted ²²⁵Ac alpha particle radioimmunotherapy

Abstract

Discussion

Cite This Study

Figure S3 from Treatment of prostate cancer with CD46 targeted ²²⁵Ac alpha particle radioimmunotherapy

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers